Japan's Takeda and enGene in GI therapy development pact

Osaka-based Takeda Pharmaceutical has lined up another gastrointestinal deal, this time to work with Montreal-based enGene to develop new treatments. Takeda will make an upfront payment and assume costs on two preclinical undisclosed targets enGene will develop using its proprietary nonviral vector platform. If milestones are met, Takeda has the option for exclusive global rights with enGene eligible for tiered royalties if the commercial stage is reached. This is the third GI pact by Takeda since December and part of a broad push in the area by the company. Release

Read more on